NCT02787707 is a Phase 2 clinical trial of Persumac in Nausea, sponsored by Mashhad University of Medical Sciences.

Who is sponsoring NCT02787707?

NCT02787707 is sponsored by Mashhad University of Medical Sciences.

What drugs are being tested in NCT02787707?

Interventions in NCT02787707: Persumac, lactose.

What condition does NCT02787707 study?

NCT02787707 studies Nausea, Vomiting.

Is NCT02787707 still recruiting?

NCT02787707 is currently completed. Last updated 2 June 2016.

Last reviewed 2016-06-02 · How we verify

NCT02787707

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ٍEffect of Iranian Traditional Medicine Remedy Compared With Placebo on Chemotherapy Induced Nausea and Vomiting in Breast Cancer; a Double-blind Randomized Controlled Cross-over Clinical Trial

Completed Phase 2 Last updated 2 June 2016

What this trial tests

Phase 2 trial testing Persumac in Nausea in 69 participants. Completed in 1 May 2016.

Timeline

1 October 2015

Primary endpoint
1 April 2016

1 May 2016

Quick facts

Lead sponsor	Mashhad University of Medical Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	69
Start date	1 October 2015
Primary completion	1 April 2016
Estimated completion	1 May 2016
Sites	1 location across Iran

Drugs / interventions tested

Persumac — full drug profile →
lactose (Lactose) — full drug profile →

Conditions studied

Nausea — all drugs for Nausea →
Vomiting — all drugs for Vomiting →

Sponsor

Mashhad University of Medical Sciences

Who can join

Adults 18 to 70, female only, with Nausea or Vomiting. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Frequency and Severity of nausea and vomiting in acute phase
Time frame: first 24 hour after chemotherapy
number and severity of nausea and vomiting, acquired from questionnaire

Sponsor's own description

The main objective of this research is the role of the Persumac(an Iranian traditional remedy) on refractory Chemotherapy Induced Nausea and Vomiting (CINV) in breast cancer patients. Investigators assess effect of Persumac on the number/severity of nausea/ vomiting in acute and delayed phase.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Persian Medicine Remedy on Chemotherapy Induced Nausea and Vomiting in Breast Cancer: A Double Blind, Randomized, Crossover Clinical Trial.
Nazari M, Taghizadeh A, Bazzaz MM, Rakhshandeh H, et al · · 2017 · cited 3× · PMID 28243404 · DOI 10.19082/3535

Verify or expand the search:

Other recruiting trials for Nausea

Currently open trials in the same condition.

NCT07378839 — Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting · NA · recruiting
NCT07523230 — Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department · NA · active not recruiting
NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
NCT06954935 — Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery · NA · recruiting
NCT06582576 — Mechanisms of Action for the Enterra Medical Gastric Electrical Stimulator · recruiting

Other Mashhad University of Medical Sciences trials

Trials by the same sponsor.

NCT06703983 — Efficacy of Low Glycemic Index Diet Versus Classic Ketogenic Diet in Pediatric Epilepsy Treatment · NA · completed
NCT06973889 — Evaluation of IgY Antibody Efficacy in Egg Yolk Against Helicobacter Pylori in Bacterial Elimination and Clinical Sympto · Phase 2 · completed
NCT05983302 — Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care · Phase 2, PHASE3 · unknown
NCT05850611 — The Effect of Combination Therapy of Oral MB and PRP-FG in Patients With Non-healing Diabetic Foot Ulcer · EARLY_PHASE1 · unknown
NCT06697444 — Risk Factors and Disorders Linked to Uterine Adenomyosis on MRI in Reproductive-Age Women · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02787707 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mashhad University of Medical Sciences
Last refreshed: 2 June 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02787707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing